|Diffusion Pharmaceuticals Inc., of Charlottesville, Va.||TSC (trans sodium crocetinate)||Vitamin A analogue||Severe respiratory symptoms and low oxygen levels in COVID-19 patients||FDA will accelerate its review of the company’s clinical development plan under the Coronavirus Treatment Acceleration Program|
|Diverse Biotech Inc., of Doylestown, Pa.||Unnamed therapy||Therapeutic using cannabidiol as a core component||Newly diagnosed glioblastoma||FDA granted orphan drug designation|
|Lipocine Inc., of Salt Lake City||LPCN-1148||Oral prodrug of bioidentical testosterone||Liver cirrhosis||FDA cleared the IND application for phase II proof-of-concept study in adult male cirrhotic patients|
|Mateon Therapeutics Inc., of Agoura Hills, Calif.||CA4P||Fosbretabulin; a vascular-disrupting agent||Stage IIB-IV melanoma due to genetic mutations that disproportionately affect pediatric patients||FDA granted rare pediatric disease designation|
|Organicell Regenerative Medicine Inc., of Miami||Organicell Flow||Acellular product derived from amniotic fluid||Moderate to severe acute respiratory syndrome due to COVID-19 infection||FDA approved the IND application|
For more information about individual companies and/or products, see Cortellis.